SCHEMBL3190686

SCHEMBL3190686

Oc1ccc2c(c1)COc1c-2cc2ccc(O)cc2c1-c1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRB O95718 3/20 0.38
ESRRA P11474 3/20 0.38
ESR2 Q92731 3/20 0.38
CYP3A4 P08684 4/20 0.36
CYP17A1 P05093 3/20 0.36
CYP11B1 P15538 3/20 0.36
CYP11B2 P19099 3/20 0.36
ESR1 P03372 2/20 0.36
CHEK1 O14757 1/20 0.35
WEE1 P30291 1/20 0.35
PRF1 P14222 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
HSD17B1 P14061 4/20 0.34
HSD17B2 P37059 4/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2B6 P20813 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3186636 0.90 CYP17A1 (0.38) ESRRBESRRAESR2CYP3A4CYP17A1
SCHEMBL3195539 0.87 ESRRB (0.50) ESRRBESRRACYP3A4CYP17A1CYP11B1
SCHEMBL3185517 0.87 ESR1 (0.40) ESRRBESRRAESR2CYP3A4CYP17A1
SCHEMBL3188483 0.87 ALOX5 (0.39) ESRRBESRRAESR2CYP3A4CYP17A1
SCHEMBL3186259 0.86 ESRRB (0.38) ESRRBESRRAESR2CYP3A4CYP17A1
SCHEMBL3198596 0.86 ESRRB (0.38) ESRRBESRRAESR2ESR1PRF1
SCHEMBL3191309 0.85 ESR2 (0.41) ESRRBESRRAESR2ESR1HSD17B1
SCHEMBL3191109 0.84 ESR2 (0.39) ESRRBESRRAESR2CYP3A4CYP17A1
SCHEMBL3187354 0.84 ESRRB (0.52) ESRRBESRRACYP3A4CYP17A1CYP11B1
SCHEMBL3189162 0.83 ESRRB (0.39) ESRRBESRRACYP11B1CYP11B2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US claimed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP claimed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US claimed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO claimed
US-7671084-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2010-03-02 US disclosed
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2007-03-01 US disclosed
US-7157492-B2 Dibenzo chromene derivatives and their use as ERβ selective ligands WYETH (US) 2007-01-02 US disclosed
EP-1718630-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ER&bgr; SELECTIVE LIGANDS Wyeth a Corporation of the State of Delaware (US) 2006-11-08 EP disclosed
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands WYETH (US) 2005-10-20 US disclosed
WO-2005082880-A1 DIBENZO CHROMENE DERIVATIVES AND THEIR USE AS ERβ SELECTIVE LIGANDS WYETH (US) 2005-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234074-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRB ESRRB 3/4885ESRRA 4/4885ESR2 1/4885
US-20070049605-A1 Dibenzo chromene derivatives and their use as ERbeta selective ligands ESR2, ESR1, ESRRA ESRRB 4/4885ESRRA 3/4885ESR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.